Germany). Skim milk: Difco Laboratories (Detroit, MI, USA). genetic aberration in human neoplasms and is thought to play Trypan blue: Seromed Berlin, Germany). Alamar blue: a key role in cancerogenesis. p53 activity is triggered by DNA BioSource (Camarillo, CA, SA). Avidin biotin peroxidase damage and results in growth arrest and DNA repair, or complex: Vector (Burlingame, CA, USA). Mouse IgG for flow apoptosis. 1 Transcriptional control of critical target genes is cytometry: Jackson Immunoresearch (West Grove, PA, USA). probably the principal mode of action by which p53 exerts Anti-glycophorin A, anti-CD117: Immunotech (Hamburg, its effects on cell growth and viability. These target genes Germany). Mouse IgG antibodies: anti-CD71, anti-CD45, include p21 (WAF/CIP-1), 2 gadd45, 3, 4 bax and bcl-2, 5-7 mdmanti-CD34, anti-CD38, anti-CD33, anti-CD3, anti-CD19, anti-2 8 and, as shown in leukemia cells, Fas/APO-1. 9 The biologi-CD20, anti-CD56, anti-CD15, anti-CD11b, anti-CD16, antical effects of wild-type p53 activity and its loss in many CD14, anti-CD61: Becton Dickinson (Heidelberg, Germany). human neoplasms have made p53 gene transfer an attractive approach of somatic gene therapy for human cancers. p53
Cell culture and transfection gene transfer has been shown to result in growth arrest and apoptosis in various tumor cells. [10] [11] [12] In contrast, the effects of K562 cells were maintained in RPMI-1640 (Gibco, Eggenstein, p53 on cellular sensitivity to cancer chemotherapy drugs have Germany). K562 cells stably expressing p53 val 135 were been controversial in that both enhanced 13, 14 and decreased obtained by electroporation (BioRad Gene Pulser (Munich, drug sensitivity [15] [16] [17] [18] [19] have been observed in cells expressing Germany), 250 V, 950 F) using the p53 val 135 Transfected cells were maintained at 38.5°C and selected with and a point mutation in exon 5 of the other allele. The latter hygromycin (200 g/ml). Single clones were selected by limitcauses an early translational stop at codon 148. 25 The bcr-abl ing dilution. translocation renders these cells resistant to multiple proapoptotic stimuli. 26 Here, we have used the temperature-sensitive at 0.1 V for 5 h and fluorescence measured at 560 nm excithat recognizes both mouse and human wild-type and mutant p53 proteins on immunoblots. In contrast to parental and tation and 590 nm emission wave lengths in a CytoFluor 2350 fluorimeter (Millipore, Bedford, MA, USA). Alternatively, the hygro K562 cells, all p53 clones exhibited strong immunoreactivity at 53 kDa ( Figure 1a ). Two clones, K562-p53-D2 and cells were centrifuged and exposed to trypan blue (0.5% in Hank's balanced salt solution) for 3 min. Apoptotic cell death K562-p53-E2, and pooled p53-transfected cells or hygro control cells were selected for further experiments. Assumption was assessed by electron microscopy, in situ DNA end labeling and quantitative DNA fluorometry. [30] [31] [32] [33] [34] of p53 wild-type conformation at 32.5°C was ascertained by immunocytochemistry using three different antibodies. Neither p53 antibody recognized parent or hygro K562 cells.
Dual-color flow cytometric surface antigen analysis
Staining with PAb421 which detects mutant and wild-type human and murine p53 confirmed that all p53-transfected Cells (10 6 Cell cycle analysis of both p53 clones at 32.5°C. Growth arrest was chiefly due to a lack of cell division and not enhanced death of cycling Cells cultured for 24-72 h at 38.5°C or 32.5°C were washed cells since only few trypan blue-positive (dead) cells were in sample buffer (DPBS, 0.1% glucose), fixed with 70% ethaobserved within 120 h at 32.5°C and since there was no nol, and stained with 1 ml of propidium iodide solution (50 increase in total K562-p53-D2 or -E2 cell counts (viable and g/ml in sample buffer containing 100 U/ml RNase A) for 30 min. All samples were analyzed on an FacsCalibur flow cytometer using the CellQuest acquisition and analysis software (Becton Dickinson).
Immunocytochemistry
Smears of K562 cells grown at 38.5°C and 32.5°C were fixed in a 1:1 mixture of acetone and methanol containing 2% formaldehyde. Immunostaining was performed as described. 35 The following concentrations of primary antibodies were used: p53 (PAb240, PAb246, PAb421): 1 g/ml; MIB1: 4 g/ml; p21: 1 g/ml, glycophorin A: 2.2 g/ml; MDM2: 1 g/ml, CD45: 3 g/ml.
Immunoblot analysis
Immunoblot analysis was performed as previously described. 31 The following concentrations of primary antibodies were used: p53 (PAb 240) 2 g/ml, p21 2 g/ml, bax 1:2000 (plus 50 mg/l ovalbumin and 0.1% human serum), MDM-2 5 g/ml, GADD45 2 g/ml (plus 50 mg/ml ovalbumin and 0.1% human serum), Bcl-2 10 g/ml. p53 and MDM-2 blots were developed using a two-step procedure with an alkaline phosphatase-conjugated secondary antibody. All other blots were developed using a three-step system with biotinylated secondary antibodies and complexes of avidin/biotin-alkaline phosphatase (Vector). prolonged time at 32.5°C. After 96 h at 32.5°C, an increased number of dying cells with either apoptotic or necrotic morphology was found. Apoptosis affected approximately 20% of K562-hygro cells and the p53 clones D2 and E2 were exposed to camptothecin, doxorubicin, cytarabine, cycloheximide, the cells and was characterized by fragmentation of nuclei into multiple electron dense bodies whereas organelles were teniposide or vincristine either at 38.5°C or 32.5°C. The shift from 38.5°C to 32.5°C per se reduced drug sensitivity in often spared (Figure 2e ). Necrotic cells, on the other hand, were surrounded by disrupted cell membranes and contained K562-hygro control cells by a factor of 1.06 for camptothecin, which is insignificant, to up to 386 for vincristine ( Figure 3 ). nuclear ghosts with marginal patches of condensed heterochromatin and extremely swollen organelles (Figure 2f) . The At 38.5°C, K562-p53-D2 and -E2 cells were markedly more sensitive to camptothecin and doxorubicin and also signifipresence of both types of cell death in transfected K562 cells was confirmed by light microscopy using sulfo-NHS-biotin for cantly more sensitive to cytarabine and cycloheximide than K562-hygro control cells. Only minor augmentation was detection of necrosis and in situ DNA end labeling for detection of apoptosis. Viable K562-p53-E2 cells showed a delicate observed for teniposide, and none for vincristine toxicity. The degree of sensitization mediated by p53 val 135 at 38.5°C, as labelling of cell membrane with sulfo-NHS-biotin and a faint diffuse in situ DNA end labeling of nuclei. Necrotic K562 cells defined by the ratio of EC 50 values of hygro cells over p53 cells was 54.5 for camptothecin, 16.5 for doxorubicin, 4.6 for were characterized by intensive labeling of the entire cytoplasm with sulfo-NHS-biotin but no in situ DNA end labeling.
cycloheximide, 1.8 for vincristine, and 1.5 for teniposide. A minor augmentation of cytotoxicity in p53-transfected cells Apoptotic cells displayed multiple nuclear fragments which were distinctively stained with the in situ DNA end labeling also became apparent at 32.5°C. The degree of sensitization fell from 54.5 at 38.5°C to 1.6 at 32.5°C for camptothecin, method. The vast majority of apoptotic K562 cells also showed an intense cytoplasmic labeling with sulfo-NHSfrom 16.6 to 4.6 for doxorubicin and from 4.6 to 4.1 for cycloheximide. Both hygro and p53-transfected cells were biotin (data not shown).
Figure 3
Temperature-sensitive modulation of drug sensitivity of K562 human myeloid leukemia cells by p53 val 135 gene transfer. K562-hygro or p53-E2 cells were seeded at 100 000 cells/ml in 96 well plates, incubated for 24 h, exposed to the drugs for 24 h, and were allowed to recover drug-free for 48 h. Viability was assessed by using the alamar blue fluorescent assay. This procedure was performed, from seeding to the viability assay, either at 38.5°C or 32.5°C. Data are expressed as means and s.e.m. of EC 50 values for drug effects on K562-hygro or p53-E2 cells. These data were estimated from serial dilutions by linear regression analysis and are derived from four separate experiments. The results for K562-p53-E2 cells were similar to those for the D2 clone (data not shown). Cytarabine failed to induce 50% cytotoxicity at concentrations up to 200 m, except for K562-p53-E2 at 38.5°C which showed half-maximal killing at 55 m cytarabine (*P Ͻ 0.01 p53-E2 vs hygro, t-test).
resistant to cytarabine at 32.5°C at concentrations up to 200 to chemosensitization induced by p53. We performed a thorough immunophenotypical analysis of K562-hygro and K562-m. Teniposide toxicity was not augmented at 32.5°C in p53 cells compared with hygro cells, and a relative induction of p53-D2 and E2 cells maintained at 38.5°C and 32.5°C. Table  1 shows results of this investigation in detail. After p53 gene chemoresistance (EC 50 ratio Ͻ1) was observed for vincristine at 32.5°C. p53-mediated sensitization to drug-induced transfer, there was an increase of glycophorin A/CD71 double positive cells and simultaneous decrease of glycophorin Aapoptosis was confirmed by enhanced DNA fragmentation, eg exposure to 1 m doxorubicin at 38.5°C induced DNA negative/CD71-positive cells as well as CD45-fluorescence intensity, suggesting erythroid differentiation, especially at fragmentation of 45% in K562-p53-E2 compared with 30% in K562-hygro cells, and at 32.5°C, 28% in K562-p53-E2 32.5°C. Further p53-induced surface marker changes were observed for CD33 (increase), CD117 (decrease), CD3 compared with 10% in K562-hygro cells.
(increase), CD19 (increase), and CD56 (increase). These changes were more prominent or occurred selectively at 32.5°C and suggested lymphoid in addition to the observed (Figure 4a ). No such effect was observed for GADD45 or Discussion MDM-2, expression of which was weak under all conditions and not modulated either by p53 gene transfer or by tempera-
The present study examined the role of a p53 gene transfer in the response to chemotherapy in K562 human myeloid leuture shift (data not shown). Expression of Bax increased within 1 h after the temperature shift in K562-p53-E2 but not in hygro kemia cells. For this purpose, we took advantage of the p53 val 135 mutant that is considered to behave as a mutant at control cells (Figure 4b ). There was high constitutive expression of Bcl-2 which was virtually unaffected by p53 38.5°C but assumes wild-type conformation and activity at 32.5°C. 27 We confirm that assumption of p53 wild-type conval 135 expression at 32.5°C (Figure 4c ). (Table 1) . A comparative study of chemosensitivity of control and p53-transfected cells at 38.5°C and 32.5°C led to the delineation of three different patterns of modulation of Next we examined whether p53-mediated changes in the immunophenotype and state of differentiation might be linked chemosensitivity by p53: (1) sensitization at 38.5°C but much less or not at 32.5°C (camptothecin, teniposide, cytarabine); p53 target genes may counteract drug-induced apoptosis, most likely by inducing growth arrest. Thus, p53 in either (2) distinct sensitization at both temperatures (doxorubicin, cycloheximide); and (3) almost no difference at 38.5°C and conformation could be a sensitizer for chemotherapy, but these effects would be masked by the transcriptional activity induction of resistance at 32.5°C (vincristine). The prominent enhancement of drug sensitivity by p53 in its presumptive of p53 at 32.5°C, this is an effect linked strictly to wildtype conformation. mutant conformation was independent of changes in growth and viability and of activation of p53 target genes such as Some previous studies [14] [15] [16] [17] [18] [19] on p53-dependent modulation of drug sensitivity need to be re-evaluated in the light of these p21, bax, gadd45 or mdm-2. Although p53 may mediate apoptosis using transcription-independent pathways, 36-38 the results. Both concepts proposed here, (1) partial redundancy of cytotoxic effects of p53 and chemotherapy rather than p53-present study does not rule out transcriptional activity of p53 at 38.5°C that may account for chemosensitization. To induced drug resistance; and (2) p53-mediated transcriptional antagonism of apoptosis, have not been appreciated when answer this question would require the use of transcriptional inhibitors such as actinomycin D which are cytotoxic and interpreting data of p53 gene transfer and cytotoxic drug treatment. Several authors document induction of resistance proapoptotic on their own, within the time frame of the experiments. There was no specific pattern of differentiation to anticancer drugs by wild-type p53 without clearly stating whether absolute survival of transfected and untransfected that could be linked to chemosensitization upon p53 expression (Table 1) . Both mutant and wild-type p53 bind to cells or relative survival compared with the untreated genetically identical control group was assessed. Resistance to cytomultiple intracellular proteins, functional depletion of which could result in changes of drug sensitivity. Introduction of toxic drugs after induction of wild-type p53 activity might occur in cells which exhibit a redistribution in the cell cycle. wild-type p53 did not generally sensitize K562 cells to cancer chemotherapy and may not decrease growth and viability of Such cells may acquire resistance to cell cycle-specific drugs and may gain sufficient time for DNA repair. Since GADD45 these cells in synergy with such drugs. Rather, there is partial redundancy of antiproliferative and cytotoxic actions of p53 is one of the candidate proteins for the link between wildtype p53 activity and DNA repair, it may not be surprising and cancer chemotherapy drugs. Drugs such as camptothecin, cytarabine, teniposide and vincristine may kill wildthat we did not observe true resistance to cancer drugs after p53 gene transfer because GADD45 was not induced. type p53-expressing cells less efficiently because the cascades activated by these drugs may have already been Finally, our data necessitate a reconsideration of the mutant/wild-type temperature sensitivity paradigm of p53 switched on by wild-type p53, and the drugs have no more cellular target to act upon. Interestingly, this does not apply val 135 . Mutant was originally defined in this paradigm by p53/hsc70 complex formation at high temperature and the for doxorubicin and cycloheximide which kill p53-transfected cells rather efficiently at 32.5°C, too. These or related lack of antiproliferative effects, suppression of transformation, PAb 1620 immunoreactivity and reporter gene transcripdrugs may therefore be promising candidates for therapeutic trials involving p53 gene transfer therapy enforced by chemotion. 27 Most of the chemosensitization and some changes in the immunophenotype of K562 cells induced by p53 gene therapy. Here, the principal difference between the action of p53 and the above-mentioned drugs was that p53 induced transfer evolved at 38.5°C and in the absence of activation of several known target genes of p53, including p21, gadd45, predominantly growth arrest whereas the drugs induced apoptosis. One might speculate that the activation of some bax, bcl-2 or mdm-2 ( Figure 4 ). The effects of p53 observed
